Zura Bio Limited · NASDAQ:ZURA
Zura Bio — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
19 slides from Zura Bio's conference presentation, Jan 11, 2024
Slide 1: Building the Next Immunology Leader
©2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Building the Next Immunology Leader 42nd Annual J.P. Morgan Healthcare Conference January 11, 2024 San Francisco, California
Slide 2: Forward Looking Statements Disclaimer
©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “antic
Slide 3: In 2023, Zura established a strong foundation to enable focused execution into 2024
© 2024 Zura Bio Ltd. ©2024 Zura Bio Ltd. 3 Began trading on Nasdaq under “ZURA” ticker ZB-106 in-licensed from Eli Lilly and Company and PIPE announced $80M PIPE closed Entered into sponsored research agreement with Benaroya Research Institute Arnout Ploos van Amstel joined Board Rob Lisicki and Dr.
Slide 4: Experienced management team with proven ability to successfully execute
©2024 Zura Bio Ltd. 4 Experienced management team with proven ability to successfully execute and build a leading market position Nasdaq: ZURA Board of Directors Executive Team Amit Munshi Arnout Ploos van Amstel Jennifer Jarrett Neil Graham, M.D. Parvinder Thiara Sandeep Kulkarni, M.D. Someit Sidhu
Slide 5: Our Strategic Approach
©2024 Zura Bio Ltd. 5 Our Strategic Approach Our approach could signify a paradigm shift for patients suffering from severe and intricate autoimmune diseases. These patients currently find their needs unmet by the conventional "single” pathway approach. We are pioneering dual pathway biology by inte
Slide 6: Systemic sclerosis is a rare & life-threatening disease with no approved therapy
©2024 Zura Bio Ltd. 6 Systemic sclerosis is a rare & life-threatening disease with no approved therapy ~200,000 people with SSc in US, EU and Japan 1 40-60% mortality in 10 years 2 Zero SSc-specific * drugs approved $2B+ annual potential market opportunity Sources: Medscape, BMJ best practice 1 Heal
Slide 7: Pioneering Dual Pathway Biology
©2024 Zura Bio Ltd. Pioneering Dual Pathway Biology 7 Sources: 1 Liu, Ling, et al. Journal of Inflammation Research, doi:10.2147/jir.s100940. 2 Manetta, Joseph et al. Journal of Inflammation Research, doi:10.2147/jir.s67751. 3 Benschop, Robert J., et al. mAbs, doi:10.1080/19420862.2019.1624463. (*)
Slide 8: Potent molecules with highly validated pathways
©2024 Zura Bio Ltd. Anti-IL-17 scFv TALTZ® Anti-BAFF Ab tabalumab BAFF IL-17 tibulizumab: BAFF / IL-17 ZB-168: IL-7R / TSLP torudokimab: IL-33 / RAGE Potent molecules with highly validated pathways Nasdaq: ZURA 78 Participants Dosed Across Three Ph1/1b studies 57 participants with single dose 21 par
Slide 9: Clinical stage pipeline targeting key immunology pathways
©2024 Zura Bio Ltd. Clinical stage pipeline targeting key immunology pathways 9 Pioneering dual pathway biology Paradigm shift for complex diseases Potential best-in-class potency on clinically validated pathways ZURA BIO PROGRAM INDICATION NEXT CLINICAL PHASE EXPECTED KEY MILESTONES Preclinical Pha
Slide 10: External Catalysts for ZB-106, ZB-168 and ZB-880 Programs
©2024 Zura Bio Ltd. 10 ZB-106 Program: External Catalyst ZB-168 Program: External Catalyst ZB-880 Program: External Catalyst LEGEND: Sources: ClinicalTrial.gov, Company Press Release Abbreviations: AA, alopecia areata; AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; HS, hidradeni
Slide 11: Potential First-in-Class, Dual Antagonist Combining tabalumab and TALTZ
©2024 Zura Bio Ltd. Potential First-in-Class, Dual Antagonist Combining tabalumab and TALTZ® systemic sclerosis (SSc) ZB-106 tibulizumab Anti-BAFF x IL-17
Slide 12: ZB-106 is Clinically De-Risked Through Ph1b
©2024 Zura Bio Ltd. ZB-106 is Clinically De-Risked Through Ph1b 12 78 Participants Dosed Across Three Ph1/1b studies 57 participants with single dose; 21 participants with multiple dose up to 12 weeks SAD Studies: No deaths or SAEs MAD study: No deaths, single related SAE of neutropenia with resolut
Slide 13: Synergistic benefit of IL-17 and BAFF Neutralization in Collagen Induced Arthritis model
©2024 Zura Bio Ltd. Synergistic benefit of IL-17 and BAFF Neutralization in Collagen Induced Arthritis model 13 Rheumatoid arthritis is a prototypic autoimmune disease where individually targeting IL-17-mediated inflammation or depleting B cells has been clinically validated The collagen-induced art
Slide 14: IL-17 and BAFF drive disease pathogenesis in systemic sclerosis
©2024 Zura Bio Ltd. IL-17 efficacy in SSc Role of BAFF in SSc IL-17 and BAFF drive disease pathogenesis in systemic sclerosis (SSc) 14 Strom al cells T1-IFN BAFF Plasm a cell CXCR5+ Tfh cell TLS GC B cell CXCL13 Brodalumab treatment in SSc leads to improved clinical outcomes 1 IL-17 known to play ke
Slide 15: IL-17 and BAFF Inhibition Have Shown Efficacy in Placebo Controlled Trials in SSc
©2024 Zura Bio Ltd. IL-17 and BAFF Inhibition Have Shown Efficacy in Placebo Controlled Trials in systemic sclerosis (SSc) 15 ZB-106 | SSc Brodalumab IL-17 receptor antagonist Achieved primary endpoint of treatment difference of least square mean: −21.2 [95% CI -23.9, 18.5]; P<0.0001), and demonstra
Slide 16: Phase 2 SSc Trial Design
©2024 Zura Bio Ltd. Phase 2 SSc Trial Design* 16 ZB-106 | SSc KEY EFFICACY ENDPOINTS • mRSS- primary • HAQ-DI (Function) • Clinician Global • Patient Global • FVC • Modified CRISS (Ph3 endpoint) (*) Trial design is subject to change due to factors such as regulatory feedback PART A: RANDOMIZED TRIAL
Slide 17: Additional Indications Under Consideration for ZB-106
©2024 Zura Bio Ltd. Additional Indications Under Consideration for ZB-106 17 ZB-106 | SSc BAFF pathway IL-17 pathway Rheumatology systemic sclerosis 1 Sjögren’s syndrome 1 systemic lupus erythematosus 1 rheumatoid arthritis 1 Dermatology hidradenitis suppurativa 1 Sources: 1 ClinicalTrials.gov BAFF
Slide 18: Development opportunities exist across Rheumatology, Respiratory and Dermatology
©2024 Zura Bio Ltd. 18 Development opportunities exist across Rheumatology, Respiratory and Dermatology ZURA ASSETS Rheumatology systemic sclerosis, Sjögren's syndrome, lupus, rheumatoid arthritis Respiratory asthma, chronic obstructive pulmonary disease Dermatology alopecia areata, hidradenitis sup
Slide 19: Thank you to J.P. Morgan Healthcare for hosting
Thank you to J.P. Morgan Healthcare for hosting Nasdaq Ticker: ZURA
Zura Bio — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix